Pawar Ajinkya, Yalla Poojitha, Sharma Mohit, Puj Ketul, Aaron Jebin, Warikoo Vikas, Salunke Abhijeet, Pandya Shashank
Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Lancet Reg Health Southeast Asia. 2025 Jul 28;40:100643. doi: 10.1016/j.lansea.2025.100643. eCollection 2025 Sep.
Breast cancer in young adult women is a rapidly growing group of cancer patients in India which needs to be addressed with urgency. Despite increasing global focus on breast cancer in young women, data from India remain scarce. Considering this gap, we undertook this study to analyse the clinicopathological characteristics and prognostic outcomes of young adult women (aged 18-30 years) with breast cancer in Ahmedabad, India.
This was a retrospective observational study of a prospectively maintained database of 201 patients with breast cancer (aged 18-30 years) treated in a high-volume tertiary centre in Ahmedabad, India, from January 2015 to December 2020. Patients were followed up until June 2023. The demographic parameters, clinicopathological characteristics and survival of all patients were studied. Statistical analyses were done using SPSS and DATAtab.
In this study 49.2% of cases were early breast cancers, 26.8% locally advanced, and 23.8% were metastatic. The proportion of aggressive cancers was higher with 38.8% hormone negative, 39.3% HER2-positive, 26.8% triple-negative and 50.8% grade 3. The median overall survival for all patients was 56 months (95% CI 28-84 months) and the 5-year overall survival was 48% (95% CI 40-56%). The multivariate analysis suggested that clinical stage, grade and luminal A status, significantly affected overall survival. The 5-year overall survival and disease-free survival of patients undergoing surgery were 65% (95% CI 57-74%) and 56% (95% CI 47-65%) respectively.
The 5-year overall survival rate of 48% among young adult women with breast cancer included in this study is poor compared to the 77% observed in high-income countries in the western parts of the world. Adoption of appropriate and aggressive treatment strategies may enhance the outcomes in this age group of women with breast cancer.
None.
在印度，年轻成年女性乳腺癌患者群体迅速增长，这一问题亟待解决。尽管全球对年轻女性乳腺癌的关注日益增加，但来自印度的数据仍然匮乏。考虑到这一差距，我们开展了这项研究，以分析印度艾哈迈达巴德市18至30岁年轻成年女性乳腺癌患者的临床病理特征和预后结果。
这是一项回顾性观察研究，对2015年1月至2020年12月在印度艾哈迈达巴德市一家大型三级中心接受治疗的201例乳腺癌患者（年龄18至30岁）的前瞻性维护数据库进行分析。对患者进行随访直至2023年6月。研究了所有患者的人口统计学参数、临床病理特征和生存率。使用SPSS和DATAtab进行统计分析。
在本研究中，49.2%的病例为早期乳腺癌，26.8%为局部晚期，23.8%为转移性乳腺癌。侵袭性癌症的比例较高，其中激素阴性占38.8%，HER2阳性占39.3%，三阴性占26.8%，3级占50.8%。所有患者的中位总生存期为56个月（95%CI 28 - 84个月），5年总生存率为48%（95%CI 40 - 56%）。多变量分析表明，临床分期、分级和腔面A型状态显著影响总生存期。接受手术患者的5年总生存率和无病生存率分别为65%（95%CI 57 - 74%）和56%（95%CI 47 - 6A%）。
本研究纳入的年轻成年女性乳腺癌患者5年总生存率为48%，与世界西部高收入国家观察到的77%相比很差。采用适当且积极的治疗策略可能会改善这一年龄组乳腺癌女性的治疗结果。
无。
